Literature DB >> 16507894

Pathogenic role of B cells in anti-CD40-induced necroinflammatory liver disease.

Kiminori Kimura1, Hisataka Moriwaki, Masahito Nagaki, Masanao Saio, Yasunari Nakamoto, Makoto Naito, Kazuo Kuwata, Francis V Chisari.   

Abstract

Activated B cells function in antibody production and antigen presentation, but whether they perform any pathophysiological functions at sites of inflammation is not fully understood. Here, we report that intravenous injection of an agonistic anti-CD40 monoclonal antibody (alphaCD40) causes a biphasic inflammatory liver disease in inbred mice. The late phase of disease was suppressed in B-cell-deficient mice and by the depletion of macrophages, but not T cells or natural killer cells. We also report that SCID mice were not susceptible to alphaCD40-induced liver disease unless they were reconstituted with normal B cells and that B cells as well as macrophages played key roles in alphaCD40-induced late phase of liver inflammation. Finally, liver disease and the recruitment of inflammatory cells into the liver were mediated by interferon-gamma and tumor necrosis factor-alpha, but not by Fas. In conclusion, these results indicate that CD40 ligation can trigger a B-cell-mediated inflammatory response that can have pathogenic consequences for the liver.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16507894      PMCID: PMC1606511          DOI: 10.2353/ajpath.2006.050314

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

1.  Precursor B cells for autoantibody production in genomically Fas-intact autoimmune disease are not subject to Fas-mediated immune elimination.

Authors:  S Hirose; K Yan; M Abe; Y Jiang; Y Hamano; H Tsurui; T Shirai
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 2.  CD40 and CD154 in cell-mediated immunity.

Authors:  I S Grewal; R A Flavell
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

Review 3.  Production of cytokines by human B cells in health and disease.

Authors:  V Pistoia
Journal:  Immunol Today       Date:  1997-07

4.  Exogenous CD40 ligand induces a pulmonary inflammation response.

Authors:  J A Wiley; R Geha; A G Harmsen
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

Review 5.  The CD40-CD154 system in anti-infective host defense.

Authors:  I S Grewal; P Borrow; E G Pamer; M B Oldstone; R A Flavell
Journal:  Curr Opin Immunol       Date:  1997-08       Impact factor: 7.486

Review 6.  Neutralizing antiviral B cell responses.

Authors:  M F Bachmann; R M Zinkernagel
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

7.  CD40-mediated stimulation of B1 and B2 cells: implication in autoantibody production in murine lupus.

Authors:  Y Kaneko; S Hirose; M Abe; H Yagita; K Okumura; T Shirai
Journal:  Eur J Immunol       Date:  1996-12       Impact factor: 5.532

8.  Enhancement of T cell-independent immune responses in vivo by CD40 antibodies.

Authors:  P Dullforce; D C Sutton; A W Heath
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

9.  Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro.

Authors:  M Naito; H Nagai; S Kawano; H Umezu; H Zhu; H Moriyama; T Yamamoto; H Takatsuka; Y Takei
Journal:  J Leukoc Biol       Date:  1996-09       Impact factor: 4.962

10.  Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver.

Authors:  M Adachi; S Suematsu; T Kondo; J Ogasawara; T Tanaka; N Yoshida; S Nagata
Journal:  Nat Genet       Date:  1995-11       Impact factor: 38.330

View more
  13 in total

1.  Line-selective macrophage activation with an anti-CD40 antibody drives a hemophagocytic syndrome in mice.

Authors:  Giada Ingoglia; Ayla Yalamanoglu; Marc Pfefferlé; Irina L Dubach; Christian A Schaer; Kristyna Valkova; Kerstin Hansen; Nadja Schulthess; Rok Humar; Dominik J Schaer; Florence Vallelian
Journal:  Blood Adv       Date:  2020-06-23

2.  BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses.

Authors:  Hyun-Il Cho; Kelly Barrios; Young-Ran Lee; Angelika K Linowski; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2012-12-25       Impact factor: 6.968

Review 3.  Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

Authors:  Barbara Rehermann; Robert Thimme
Journal:  Gastroenterology       Date:  2018-09-26       Impact factor: 22.682

4.  Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis.

Authors:  Jun Yu; Alex Y Hui; Eagle S H Chu; Alfred S L Cheng; Minnie Y Y Go; Henry L Y Chan; Wai K Leung; Kin F Cheung; Arthur K K Ching; Yiu L Chui; Ka K Chan; Joseph J Y Sung
Journal:  Gut       Date:  2006-12-05       Impact factor: 23.059

5.  Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity.

Authors:  Manoj Thapa; Raghavan Chinnadurai; Victoria M Velazquez; Dana Tedesco; Elizabeth Elrod; Jin-Hwan Han; Prachi Sharma; Chris Ibegbu; Andrew Gewirtz; Frank Anania; Bali Pulendran; Mehul S Suthar; Arash Grakoui
Journal:  Hepatology       Date:  2015-03-25       Impact factor: 17.425

6.  STING agonists induce an innate antiviral immune response against hepatitis B virus.

Authors:  Fang Guo; Yanxing Han; Xuesen Zhao; Jianghua Wang; Fei Liu; Chunxiao Xu; Lai Wei; Jian-Dong Jiang; Timothy M Block; Ju-Tao Guo; Jinhong Chang
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

Review 7.  Engineering nano- and microparticles to tune immunity.

Authors:  James J Moon; Bonnie Huang; Darrell J Irvine
Journal:  Adv Mater       Date:  2012-05-29       Impact factor: 30.849

8.  Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

Authors:  Cory L Ahonen; Anna Wasiuk; Shinichiro Fuse; Mary Jo Turk; Marc S Ernstoff; Arief A Suriawinata; James D Gorham; Ross M Kedl; Edward J Usherwood; Randolph J Noelle
Journal:  Blood       Date:  2008-01-17       Impact factor: 22.113

9.  Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.

Authors:  Juliana Hamzah; Delia Nelson; Gerd Moldenhauer; Bernd Arnold; Günter J Hämmerling; Ruth Ganss
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

10.  Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy.

Authors:  Brandon Kwong; Haipeng Liu; Darrell J Irvine
Journal:  Biomaterials       Date:  2011-04-22       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.